BridgeMD
Daily versus alternate day oral iron supplementation for the treatment of iron deficiency anaemia in pregnancy (IronMother)
EU CTIS ID: 2024-512064-61-00
What this study is testing
To determine whether alternate day oral iron is noninferior to daily oral iron for the treatment of iron deficiency anaemia by comparing haemoglobin level (Hb) between the two arms after 4 weeks of therapy
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol
- Subjects must be aged 18 years or above at visit 1
- Subjects will need to have a standard of English good enough to understand and read the information leaflet and consent form and communicate easily with the research team
- A diagnosis of IDA as defined by Hb <10.5g/dL but not ≤7g/dl and a serum ferritin of <30µg/L
- Singleton pregnancies
- Gestational age of 14- 34 weeks’ gestation
You likely can't join if
- Women <18 years of age
- Allergy/sensitivity to Galfer or their ingredients
- Subjects unable to provide written informed consent or who require an interpreter
- Known haemoglobinopathy
- Severe anaemia as defined by Hb ≤7g/dl
- Subjects who have any other significant disease or disorder (including inflammatory bowel disease, haemochromatosis, haemoglobinopathy, any active inflammatory diseases, malabsorptive conditions) which, in the opinion of the investigator, may either put the subject at risk by participation in the study, or may influence the result of the study.
See the full eligibility criteria
- Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol
- Subjects must be aged 18 years or above at visit 1
- Subjects will need to have a standard of English good enough to understand and read the information leaflet and consent form and communicate easily with the research team
- A diagnosis of IDA as defined by Hb <10.5g/dL but not ≤7g/dl and a serum ferritin of <30µg/L
- Singleton pregnancies
- Gestational age of 14- 34 weeks’ gestation
- A level of English high enough for informed consent and study participation
- Women <18 years of age
- Allergy/sensitivity to Galfer or their ingredients
- Subjects unable to provide written informed consent or who require an interpreter
- Known haemoglobinopathy
- Severe anaemia as defined by Hb ≤7g/dl
- Subjects who have any other significant disease or disorder (including inflammatory bowel disease, haemochromatosis, haemoglobinopathy, any active inflammatory diseases, malabsorptive conditions) which, in the opinion of the investigator, may either put the subject at risk by participation in the study, or may influence the result of the study.
- Any underlying medical disorder or medications that the research team feel would impact iron absorption eg. Hyperemesis, Coeliac’s disease, inflammatory bowel disease, anaemia of chronic disease or anaemia related to other causes (B12/Folate), previous bariatric surgery, active PUD, haemochromatosis
- Multiple pregnancy
- Not taking medications in a way which could potentially hinder the absorption of iron eg. PPIs, Antacids, levothyroxine all need to be taken separately to iron
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.